LSD Conference Recap: IMIO Life

The article LSD Conference Recap: IMIO Life was originally published on Microdose.

IMIO Life is a psychedelic medicine company based in Israel, “dedicated to finding novel solutions for debilitating neurological disorders affecting millions of patients and their families. The approach is to combine known molecules with our unique drug delivery technology, enabling better penetration of molecules into the brain, reducing the therapeutic dose, providing a safer treatment while minimizing adverse effects”

Dr. Tal Hasson, Chief Technology Officer, led a presentation on Overcoming the Lingering Effects of LSD at our recent LSD Conference. Dr. Hasson gave a very in-depth look at how LSD works in the body and the brain, with the goal of optimizing future delivery mechanisms. Here are some highlights. 

“…we can see that LSD doesn’t stay in the brain for long. It’s out of the brain, but not out of the system..”

“So what is happening is that LSD is concentrated and settles within the digestive tract and it takes it a longer time to actually get eliminated from the digestive tract. So one of the assumptions that we’re thinking of is that it’s not only that you have a slow dissociation of LSD from the 5HT2A. It’s also discontinued. Leakage. Probably into the circulatory system and then re-penetration of the brain.”

“So if you combine these two factors together you are going to get a prolonged effect. And then your therapeutic window is going to be much wider, then if you were trying to find out how to treat something in a short duration..”

“Imagine you were able to exclusively target the brain, and thereby minimize the systemic exposure. Then that gives you another level of confidence in which you can probably lower the therapeutic dose. And if we look at the fact that we have a complicated molecule, an expensive molecule — so if we can further reduce the therapeutic dose, which would be much more effective and potentially lowering the price of the drug.”

Very important analysis for the future of delivering future therapeutic treatments at scale.

See below for a look at the Q&A with Dr. Hasson. And check out IMIO’s website here for more information on their work.

Read More